Arrowhead Pharmaceuticals participated in the ESC Congress 2025.
3 reports, 2 independent
Updated Jul 22
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Arrowhead Pharmaceuticals participated in the ESC Congress 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Arrowhead announced its Nasdaq listing and plans a U.S. regulatory filing alongside ESC presentation.1 source
Arrowhead Pharmaceuticals participated in the ESC Congress 2025.1 source
Keep exploring
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
European Society of Cardiology
non-profit knowledge-based professional association
Related events
- Tenax Therapeutics presented findings and announced results at the European Society of Cardiology Congress 2026.
- Trial results regarding HeartFlow Inc. were presented at the ESC Congress, focusing on how AI technology supports the guidelines of the American College of Cardiology.
- Research addressing limitations in ESC guidelines was presented, involving Aalborg University and Aamir Mahmood.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- Business WireArrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences PASADENA, Calif., August 27, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that